Latest Breaking News On - Single agent - Page 5 : comparemela.com

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial .

United statesGregory lubinieckiMerck research laboratoriesEuropean unionEuropean organisation for researchMerck co incExchange commissionEuropean commissionStatement of merck co incEuropean medicines agencyMedicinal productsHuman useMerck researchEuropean organisationEuropean thoracic oncology platformSelected important safety

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

United statesDomenica lorussoGursel aktanEuropean network for gynaecological oncology trialFoundation incExchange commissionCatholic university of romeStatement of merck co incData monitoring committeeMerck co incMerck research laboratoriesMerck researchCatholic universityEuropean networkGynaecological oncology trialSelected important safety

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulie cunninghamChrissy trankScot ebbinghausDamini chokshiPeter dannenbaumExchange commissionMerck co incMerck research laboratoriesData monitoring committeeStatement of merck co incMerck researchSelected important safetyImportant safety informationFatal immune mediated adverse reactionsImmune mediated hepatitis

Merck (MRK) Provides Update on Phase 3 KEYNOTE-585 Trial

Merck (MRK) Provides Update on Phase 3 KEYNOTE-585 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChrissy trankPeter dannenbaumJulie cunninghamDamini chokshiScot ebbinghausExchange commissionMerck co incData monitoring committeeStatement of merck co incMerck research laboratoriesMerck researchSelected important safetyImportant safety informationFatal immune mediated adverse reactionsSingle agent

Kinnate Biopharma : Results of Operations and Financial Condition - Form 8-K

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a. | April 17, 2023

United statesPriyanka shahRichard williamsAlexander spiraNima farzanVirginia cancer specialists research instituteKinnate biopharma incExchange commissionAmerican association for cancer researchFirst reportInvestigational exarafenibSingle agentClinical trials mini symposium sessionAmerican associationCancer researchVirginia cancer specialists research